scFv(Control)-CD28-CD3zeta CAR-T Lentivirus

The scFv(Control)-CD28-CD3zeta CAR-T Lentivirus is a standardized tool designed for the rigorous validation of second-generation CAR-T cell therapies. This lentiviral vector facilitates the expression of a chimeric antigen receptor that incorporates a non-targeting single-chain variable fragment (scFv) as its extracellular sensing element. This mock scFv is fused via a hinge and transmembrane region to the CD28 co-stimulatory endodomain and the CD3ζ primary signaling domain. By utilizing a high-titer lentiviral delivery system, the construct is stably integrated into the host T-cell genome, ensuring persistent expression across multiple cell divisions. This specific configuration allows researchers to maintain the structural and intracellular signaling integrity of a standard second-generation CAR while eliminating antigen-specific recognition, providing a crucial benchmark for therapeutic assays.

The applications of this control lentivirus are central to preclinical development and mechanistic studies. It is primarily employed as a negative control in cytotoxicity assays, such as chromium release or luciferase-based killing assays, to accurately subtract background cell lysis from targeted, antigen-driven lytic activity. Beyond simple killing assays, it serves as a vital reference for assessing “tonic signaling,” a phenomenon where CAR-T cells exhibit spontaneous activation and exhaustion in the absence of an antigen. By comparing the baseline cytokine production and phenotypic markers of cells transduced with this control virus against those of antigen-specific CAR-T cells, scientists can isolate the metabolic and transcriptional changes triggered solely by antigen binding. Additionally, it is used to validate that any observed off-target effects or systemic toxicities in in vitro models are not inherent to the viral transduction process or the constitutive expression of the CD28-CD3ζ signaling scaffold.